Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and The Health Care Select Sector SPDR Fund (XLV) up 0.3%.

Invivyd (IVVD) shares were down past 28% after the company said the US Food and Drug Administration rejected its request to expand the existing emergency use authorization for Pemgarda to include treatment of mild-to-moderate COVID-19 in immunocompromised adults and adolescents.

Summit Therapeutics (SMMT) stock was over 5% higher after the company said it will collaborate with Pfizer (PFE) on a set of clinical trials to evaluate ivonescimab, its investigational drug, in combination with several Pfizer antibody drug conjugates to treat multiple solid tumors.

Entrada Therapeutics (TRDA) shares were up more than 5% after the company said the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.